RayzeBio, Inc. (RYZB)
| Market Cap | 3.73B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -66.34M |
| Shares Out | 60.02M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 895,422 |
| Open | 61.75 |
| Previous Close | 61.67 |
| Day's Range | 61.60 - 62.26 |
| 52-Week Range | 17.95 - 62.26 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.33 (-49.61%) |
| Earnings Date | Feb 15, 2024 |
About RYZB
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that ta... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for RYZB stock is "Strong Buy." The 12-month stock price forecast is $31.33, which is a decrease of -49.61% from the latest price.
News
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (...
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic...
Bristol to Buy Drug Developer RayzeBio for $4.1 Billion
Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg's Madison Mueller reports.
The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio
Jared Hopkins, Wall Street Journal, joins 'The Exchange' to discuss Bristol-Myers Squibb's plan to buy RayzeBio.
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options....
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive territ...
Shareholder Alert: Ademi LLP investigates whether RayzeBio, Inc. has obtained a Fair Price in its transaction with Bristol Myers
MILWAUKEE , Dec. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating RayzeBio (NASDAQ: RYZB) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers. ...
RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RayzeBio, Inc. (NASDAQ: RYZB) to Bristol-Myers Squibb Company for $62.50 per share in cas...
Bristol Myers to buy RayzeBio for about $4.1B
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies
Dec 26 (Reuters) - Bristol Myers Squibb (BMY.N) said on Tuesday it would buy RayzeBio (RYZB.O) for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal ...
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
RayzeBio is being bought for $62.50 a share in cash.
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franc...
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion
Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers ...
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today report...
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announce...
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announ...
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing o...
RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion
Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% above the initial public offering price. The company ...
RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offering priced at the top end of the expected range. T...
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing o...
RayzeBio sets IPO terms, to be valued at up to $1 billion
RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Phase 3 trial looks to raise up to about $238.2 milli...
RayzeBio Appoints Christy Oliger to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of dir...
RayzeBio IPO Registration Document (S-1)
RayzeBio has filed to go public with an IPO on the NASDAQ.